India’s first indigenous CAR-T cell therapy, NexCAR19, developed by ImmunoACT, an IIT Bombay spin-off, marks a major leap in affordable cancer care. Supported by DBT and BIRAC, the therapy reprograms a patient’s immune cells to fight blood cancers like Acute Lymphocytic Leukemia (ALL). Clinical trials at Tata Memorial Centre have shown promising results, positioning India as a rising hub for cell and gene therapy innovation.
